2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4205 Lower population pharmacokinetic-predicted fludarabine exposure is associated with reduced non-relapse mortality and improved overall survival after fludarabine/cyclophosphamide reduced-intensity conditioning hematopoietic cell transplantation for hematologic malignancies

Biplov Adhikari, MBBS, Keith T. Schmidt, PhD2, Henry Roberts, PhD3, Matthias Zanker, MD4, Winnie Trang5, William Figg, PhD6, Steven Z. Pavletic, MD, PhD7, Eduard Schulz, MD, PhD8, Najla El Jurdi, MD9
1 National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States
2 National Cancer Institute, Bethesda, Maryland, United States
3 National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States
4 Medical University of Graz, Graz, Austria
5 National Institutes of Health, Bethesda, Maryland, United States
6 National Cancer Institute, Bethesda, Maryland, United States
7 National Cancer Institute, Bethesda, Maryland, United States
8 Medical University of Graz, Graz, Austria
9 National Cancer Institute, Bethesda, Maryland, United States

Introduction: Fludarabine (Flu) is one of the most used agents for reduced intensity conditioning (RIC) in allogeneic hematopoietic cell transplantation (HCT). It is commonly dosed based on body surface area (BSA) and provides immunosuppression and lymphodepletion to facilitate donor engraftment. However, there is growing evidence that BSA-based dosing results in significant interindividual variability in Flu exposure, and non-optimal exposure has been associated with inferior outcomes. Population pharmacokinetic (popPK)-guided dosing has been associated with improved outcomes in patients undergoing myeloablative conditioning (MAC). However, these popPK-based Flu exposure thresholds have not yet been validated in adults undergoing RIC HCT. Our primary objective was to validate the optimal popPK-based Flu exposure thresholds described by Langenhorst et al. for MAC in a cohort of patients with hematological malignancies undergoing RIC HCT. If these thresholds could not be validated, we preplanned an exploratory analysis to identify a Flu exposure threshold associated with improved 1-year overall survival (OS) in our cohort.

Methods: This is a retrospective single center analysis that included adult patients undergoing HLA-matched (8/8) or mismatched (7/8) unrelated donor (MUD/mMUD) peripheral blood stem cell transplantation (PBSCT) after RIC for hematologic malignancies on two prospective clinical trials (NCT02356159; NCT00520130). Flu PK was simulated using a popPK model adapted from Langenhorst et al., which demonstrated body weight and estimated glomerular filtration rate (eGFR) to be strong predictors of drug exposure (i.e., cumulative area under the curve over 4 Flu doses [cAUC]). We supplemented the prospectively collected outcomes data with retrospectively calculated popPK Flu cAUC.

Results: A total of 114 patients who underwent HCT from 10/2007 to 11/2022 were included. Conditioning consisted of Flu (30 mg/m2/day) and cyclophosphamide (1200 mg/m2/day) administered on days −6 to −3. Patients with creatinine clearance <70 mL/min/1.73 m2 received a 20% dose reduction. Graft-versus-host disease (GVHD) prophylaxis consisted of either tacrolimus, methotrexate, and sirolimus (TMS) or alemtuzumab and cyclosporine (AC). The median recipient age was 40 years (interquartile range [IQR]: 34.3-57.9). Most patients were males (63.2%) and white, non-Hispanic (76.3%). Overall, 63% had a Karnofsky performance score (KPS) of ≥90; 67.5% had an HCT‑specific comorbidity index (HCT-CI) ≥2, and 63.2% were CMV‑seropositive. The most common indication for HCT was B-NHL (26.3%), followed by CLL (15.8%), AML/MDS (14.9%), and ALL (13.2%). Most patients received a MUD PBSCT (84.2%). The median follow-up among surviving patients in our study was 5.15 years (95% CI: 5.02-6.31).

The median Flu cAUC for the entire cohort was 17.6 mg*hr/L (IQR: 15.2-20.6). We found no significant differences in the cumulative incidence of relapse, non-relapse mortality (NRM), and OS when comparing between the previously defined optimal Flu exposure range (cAUC: 15-20 mg*hr/L) vs. non-optimal (either <15 or >25 mg*hr/L) as per Langenhorst et al. in their cohort of MAC recipients.

However, our exploratory analysis identified a Flu cAUC threshold of <18 mg*hr/L that was associated with improved OS compared with ≥18 mg*hr/L. The 1-year OS was 75.0% (95% CI: 62.0–84.1%) among patients with Flu cAUC <18 mg*hr/L vs. 60.4% (95% CI: 46.0–72.1%) among those with Flu cAUC ≥18 mg*hr/L. The improvement in OS was significant for Flu cAUC threshold of <18 mg*hr/L even after adjusting for HCT-CI, KPS, recipient CMV-serostatus, HLA-match, and GVHD-prophylaxis regimen (HR=0.56, 95% CI: 0.34-0.91; P=0.02). A Flu cAUC of <18 mg*hr/L was also associated with a lower cumulative incidence (CI) of NRM (sHR=0.42, 95% CI: 0.21-0.83; P=0.01) but not with an increased relapse risk (sHR=1.11, 95% CI: 0.53-2.0; P=0.81) or a significant difference in GHVD-free, relapse-free survival (GRFS; HR=1.00, 95% CI: 0.63-1.43; P=0.93).

Conclusion: Lower popPK-predicted fludarabine exposure was associated with lower NRM and improved OS in patients undergoing fludarabine/cyclophosphamide RIC HCT. These findings suggest that popPK-guided Flu-dosing targeting lower exposure may reduce transplant-related toxicity and improve clinical outcomes without increasing relapse. External validation of these findings is currently underway.
Biplov Adhikari, MBBS: No relevant conflicts of interest to declare.